Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.4K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.4K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.3K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.3K
Disorders of the Autonomic Nervous System01:18

Disorders of the Autonomic Nervous System

1.3K
The autonomic nervous system (ANS) is an intricate network of nerves that controls functions such as the regulation of heart rate, digestion, and blood pressure regulation. When this system malfunctions, it can lead to various disorders that affect multiple bodily functions. One common feature of many autonomic disorders is the involvement of smooth blood vessels, which play a crucial role in regulating blood flow throughout the body.
Raynaud's disease, also known as Raynaud's...
1.3K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

657
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
657
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

1.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

790
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
790

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temporary Mechanical Support as a Bridge to Transcatheter Aortic Valve Replacement in Cardiogenic Shock.

JACC. Case reports·2026
Same author

Appropriateness of patients transferred with orthopaedic injuries: a retrospective study of a Level III teaching hospital.

OTA international : the open access journal of orthopaedic trauma·2026
Same author

Branch retinal artery occlusion time to presentation and diagnosis: a retrospective review.

International journal of retina and vitreous·2026
Same author

Branch Retinal Artery Occlusion Visual Outcomes: A Community-Based Study.

Ophthalmology. Retina·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Alzheimer's Imaging Consortium.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: Dec 17, 2025

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.0K

Metoprolol-Associated Central Nervous System Complications.

Rony Shah1, Alina Babar2, Amar Patel2

  • 1Internal Medicine, HCA Citrus Memorial Hospital, Inverness, USA.

Cureus
|June 26, 2020
PubMed
Summary

Metoprolol, a common cardiovascular drug, can cause central nervous system side effects in elderly patients. Close monitoring for neurological symptoms is crucial when initiating beta-blocker therapy in this population.

Keywords:
beta-blocker side effectsbizzare and vivid dreamscns side effectsdeliriummetoprolol side effectsmetoprolol therapymetoprolol toxicitysleep disturbances

More Related Videos

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.1K

Related Experiment Videos

Last Updated: Dec 17, 2025

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.0K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.1K

Area of Science:

  • Geriatric Medicine
  • Pharmacology
  • Neurology

Background:

  • Metoprolol is frequently prescribed to elderly individuals for cardiovascular disease due to its efficacy and affordability.
  • Beta-blocker therapy, particularly with lipophilic agents, is associated with central nervous system (CNS) side effects.

Observation:

  • An 84-year-old male presented with a four-week history of confusion, fatigue, lightheadedness, nightmares, sleep disturbances, and gait issues.
  • Neurogenic and cardiogenic etiologies for the patient's symptoms were investigated and excluded.

Findings:

  • The patient's neurological symptoms are suspected to be linked to his medication regimen, necessitating a thorough review of his medical chart and reconciliation.
  • Central nervous system side effects of beta-blockers in the elderly can manifest as psychiatric conditions, vivid dreams, delirium, psychosis, and hallucinations.

Implications:

  • This case highlights the importance of recognizing and monitoring for potential CNS adverse effects of metoprolol in the elderly population.
  • Pharmacological management in geriatric patients requires careful consideration of drug properties, such as lipophilicity, and potential side effects.
  • Enhanced vigilance and medication reconciliation are essential to ensure patient safety and optimize therapeutic outcomes in elderly patients on beta-blockers.